Aerosol tyrosine kinase inhibitor compounds and uses thereof

Inhalation delivery formulations of tyrosine kinase inhibitors like imatinib and phenylaminopyrimidine derivatives address the limitations of existing treatments for lung and systemic diseases by enhancing target organ doses and safety profiles.

JP7578258B2Active Publication Date: 2024-11-06AVALYN PHARMA INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020030935
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2014-03-05
Filing Date
2020-02-26
Publication Date
2024-11-06
Estimated Expiration
2034-07-31

AI Technical Summary

Technical Problem

Many lung diseases such as interstitial lung disease and cancer, as well as viral infections, lack effective treatments, and existing therapies fail to optimize target organ doses, pharmacokinetic profiles, and safety, necessitating improved inhalation delivery methods for kinase inhibitors.

Method used

Development of liquid, dry powder, and metered-dose formulations of tyrosine kinase inhibitors like imatinib and phenylaminopyrimidine derivatives for inhalation delivery to lungs, central nervous system, and systemic compartments, utilizing formulations with specific concentrations, osmotic agents, and pH buffers to enhance efficacy and safety.

Benefits of technology

Enhances target organ doses and safety profiles, improving treatment outcomes for pulmonary, nervous system, and cardiovascular diseases by optimizing inhalation delivery of kinase inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578258000062
    Figure 0007578258000062
  • Figure 0007578258000063
    Figure 0007578258000063
  • Figure 0007578258000064
    Figure 0007578258000064
Patent Text Reader

Abstract

To provide compositions of imatinib, phenylaminopyrimidine derivative and kinase inhibitor compounds that are suitable for inhalation delivery to the lungs, central nervous system and / or systemic compartment, and methods of using the same.SOLUTION: A unit dosage of an aqueous solution for nebulized inhalation administration comprises: about 0.01 mL to about 10 mL of water; and a nintedanib salt at a concentration of about 0.1 mg / mL to about 100 mg / mL, where the osmolality of the aqueous solution is from about 50 mOsmol / kg to about 2000 mOsmol / kg.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] <Priority Claim> This application claims the benefit of U.S. Provisional Patent Application No. 61 / 860,721, filed July 31, 2013, entitled "AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF"; and U.S. Provisional Patent Application No. 61 / 948,461, filed March 5, 2014, entitled "AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF"; all of which are incorporated herein by reference in their entireties.

[0002] FIELD OF THE INVENTION In its various embodiments, the present invention relates to liquid, dry powder, and metered-dose formulations for therapeutic inhalation delivery of phenylaminopyrimidine derivative compositions, such as imatinib and other kinase inhibitor compounds, to desired anatomical sites for the treatment and / or prevention of various pulmonary, neurological, cardiovascular, and solid organ disease conditions. [Background technology]

[0003] Despite the development of many promising treatments, many pulmonary diseases, such as interstitial lung disease (ILD; and its subclasses), cancer, and many viral infections, remain areas of unmet clinical need. Via inhalation, target organ dose, pharmacokinetic profile, and safety profile may be improved to enhance efficacy and safety and reduce patient tolerance. Additionally, many extrapulmonary diseases may also benefit from inhaled delivery or other direct application to affected tissues. Described herein are compositions of imatinib, a phenylaminopyrimidine derivative, and kinase inhibitor compound suitable for inhaled delivery to the lung, central nervous system, and / or systemic compartments, and methods of use thereof. Summary of the Invention

[0004] According to certain embodiments of the present invention, compositions are provided that are formulations comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or a kinase inhibitor or a salt thereof, or a compound of imatinib, a phenylaminopyrimidine derivative, or a kinase inhibitor or a salt thereof for oral, pulmonary, or intranasal inhalation delivery, for the prevention or treatment of various fibrotic diseases, including diseases associated with the lungs, heart, kidneys, liver, eyes, and central nervous system; cancers, including cancers associated with the lungs, heart, kidneys, liver, eyes, and central nervous system; and hypertensive diseases, including diseases associated with the lungs, heart, kidneys, liver, and peripheral vascular system, wherein the compositions include formulations for aerosol administration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a kinase inhibitor or a salt thereof.

[0005] In some embodiments, the tyrosine kinase inhibitor or a salt thereof is a compound of a phenylaminopyrimidine derivative or a salt thereof. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is imatinib or a salt thereof. In some embodiments, a salt of the tyrosine kinase inhibitor is used. In some embodiments, a phosphate salt of the tyrosine kinase inhibitor is used.

[0006] In one aspect, described herein is an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.1 mg / mL to about 100 mg / mL. In another aspect, described herein is an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.1 mg / mL to about 100 mg / mL; one or more inorganic salts at a concentration of about 0.1% to about 1.0% to adjust osmolality and provide osmotic ions; and, optionally, one or more buffering agents to maintain a pH between about pH 4.0 and about pH 8.0. In some embodiments, the aqueous solution comprises one or more inorganic salts selected from sodium chloride and magnesium. In some embodiments, the aqueous solution comprises sodium chloride. In some embodiments, the aqueous solution comprises magnesium chloride. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.2% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.3% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.4% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.5% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.9%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.8%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.7%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.6%. In some embodiments, the pH of the aqueous solution is about pH 4.0 to about pH 8.0. In some embodiments, the pH of the aqueous solution is about pH 5.0 to about pH 8.0. In some embodiments, the pH of the aqueous solution is about pH 4.0 to about pH 7.0. In some embodiments, described herein are aqueous solutions for nebulized inhalation administration, the aqueous solutions comprising: water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; and wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg.In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.001 mg / mL to about 200 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.01 mg / mL to about 200 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.01 mg / mL to about 150 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.01 mg / mL to about 100 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.01 mg / mL to about 50 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 40 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 200 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 150 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 100 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 50 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 40 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 30 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 20 mg / mL. In some embodiments, the tyrosine kinase inhibitor or salt thereof is at a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg, hi some embodiments, the osmolality of the aqueous solution is about 100 mOsmol / kg to about 1000 mOsmol / kg.In some embodiments, the aqueous solution has an osmolality of about 100 mOsmol / kg to about 750 mOsmol / kg, about 100 mOsmol / kg to about 500 mOsmol / kg, about 200 mOsmol / kg to about 2000 mOsmol / kg, about 200 mOsmol / kg to about 1000 mOsmol / kg, about 200 mOsmol / kg to about 750 mOsmol / kg, or about 200 mOsmol / kg to about 500 mOsmol / kg. In some embodiments, the solution further comprises one or more additional components selected from a co-solvent, a tonicity agent, a sweetener, a surfactant, a humectant, a chelating agent, an antioxidant, an inorganic salt, and a buffer. In some embodiments, the solution further comprises one or more additional components selected from a taste masking agent / sweetener, and an inorganic salt. In some embodiments, the taste-masking agent / sweetener is saccharin or a salt thereof. In some embodiments, the aqueous solution comprises one or more buffers selected from a citrate buffer and a phosphate buffer. In some embodiments, the aqueous solution comprises a phosphate buffer. In some embodiments, the aqueous solution comprises a citrate buffer. In some embodiments, the aqueous solution comprises a citrate buffer or a phosphate buffer; and sodium chloride, sodium bromide, or magnesium chloride. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is a phenylaminopyrimidine derivative or a salt thereof. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is imatinib or a salt thereof. In some embodiments, a salt of a tyrosine kinase inhibitor is used. In some embodiments, a phosphate salt of a tyrosine kinase inhibitor is used. In some embodiments, the salt of a tyrosine kinase inhibitor provides its own buffering capacity. In some embodiments, the present specification provides about 0.01 mL to about 6 mL of an aqueous solution described herein. In some embodiments, described herein is about 0.5 mL to about 6 mL of an aqueous solution described herein.

[0007] In another aspect, the present specification describes an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 100 mg / mL. In another aspect, the present specification describes an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 100 mg / mL; one or more inorganic salts at a concentration of about 0.1% to about 1.0% to adjust osmolality and provide osmotic ions; and optionally, one or more buffers to maintain a pH between about pH 4.0 and about pH 8.0. In some embodiments, the aqueous solution comprises one or more inorganic salts selected from sodium chloride and magnesium chloride. In some embodiments, the aqueous solution comprises sodium chloride. In some embodiments, the aqueous solution comprises magnesium chloride. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.2% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.3% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.4% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.5% to about 1.0%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.9%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.8%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.7%. In some embodiments, the inorganic salt content of the aqueous solution is about 0.1% to about 0.6%. In some embodiments, the pH of the aqueous solution is about pH 4.0 to about pH 8.0. In some embodiments, the pH of the aqueous solution is from about pH 5.0 to about pH 8.0. In some embodiments, the pH of the aqueous solution is from about pH 4.0 to about pH 7.0.In some embodiments, the present specification describes an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the present specification describes an aqueous solution for nebulized inhalation administration, the aqueous solution comprising: water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 100 mg / mL; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the imatinib or a salt thereof, or the phenylaminopyrimidine derivative or a salt thereof, is at a concentration of about 0.001 mg / mL to about 200 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.01 mg / mL to about 200 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.01 mg / mL to about 150 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.01 mg / mL to about 100 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.01 mg / mL to about 50 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 40 mg / mL. In some embodiments, the imatinib or a salt thereof, or the phenylaminopyrimidine derivative or a salt thereof compound is at a concentration of about 0.5 mg / mL to about 50 mg / mL, hi some embodiments, the imatinib or a salt thereof, or the phenylaminopyrimidine derivative or a salt thereof compound is at a concentration of about 1 mg / mL to about 50 mg / mL.In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 2 mg / mL to about 50 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 1 mg / mL to about 25 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 2 mg / mL to about 50 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 2 mg / mL to about 40 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 200 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 150 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 100 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 50 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 40 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is at a concentration of about 0.1 mg / mL to about 30 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, has a concentration of about 0.1 mg / mL to about 20 mg / mL. In some embodiments, imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, has a concentration of about 0.1 mg / mL to about 10 mg / mL. In some embodiments, the aqueous solution has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg.In some embodiments, the aqueous solution has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the aqueous solution has an osmolality of about 100 mOsmol / kg to about 750 mOsmol / kg, about 100 mOsmol / kg to about 500 mOsmol / kg, about 200 mOsmol / kg to about 2000 mOsmol / kg, about 200 mOsmol / kg to about 1000 mOsmol / kg, about 200 mOsmol / kg to about 750 mOsmol / kg, or about 200 mOsmol / kg to about 500 mOsmol / kg. In some embodiments, the solution further comprises one or more additional components selected from a co-solvent, a tonicity agent, a sweetener, a surfactant, a humectant, a chelating agent, an antioxidant, an inorganic salt, and a buffer. In some embodiments, the solution further comprises one or more additional ingredients selected from taste-masking agents and inorganic salts. In some embodiments, the taste-masking agent / sweetener is saccharin or a salt thereof. In some embodiments, the aqueous solution comprises one or more buffers selected from a citrate buffer and a phosphate buffer. In some embodiments, the aqueous solution comprises a phosphate buffer. In some embodiments, the aqueous solution comprises a citrate buffer. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; optionally, a phosphate buffer that maintains the pH of the solution at about pH 4.0 to about pH 8.0, or a citrate buffer that maintains the pH of the solution at about pH 4.0 to about 7.0; and optionally, sodium saccharin at a concentration of about 0.01 mM to about 10 mM; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and optionally, sodium saccharin at a concentration of about 0.01 mM to about 10 mM; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg.In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; optionally sodium chloride; and optionally sodium saccharinate at a concentration of about 0.01 mM to about 10 mM; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a salt of imatinib or a phenylaminopyrimidine derivative is used. In some embodiments, a phosphate salt of imatinib or a phenylaminopyrimidine derivative is used. In some embodiments, the salt of imatinib or the salt of a phenylaminopyrimidine derivative provides buffering capacity by itself. In some embodiments, the present specification describes an aqueous solution described herein, which is about 0.01 mL to about 6 mL. In some embodiments, described herein is about 0.5 mL to about 6 mL of an aqueous solution described herein.

[0008] In some embodiments, the aqueous solution comprises water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; and optionally a phosphate buffer that maintains the pH of the solution at about pH 4.0 to about pH 8.0; wherein the osmolality of the aqueous solution is about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is a phenylaminopyrimidine derivative or a salt thereof. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is imatinib or a salt thereof.

[0009] In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; and optionally a phosphate buffer that maintains the pH of the solution at about pH 4.0 to about pH 8.0; wherein the osmolality of the aqueous solution is about 100 mOsmol / kg to about 1000 mOsmol / kg.

[0010] In some embodiments, the aqueous solution comprises water; a salt of imatinib or a salt of a phenylaminopyrimidine derivative at a concentration of about 0.001 mg / mL to about 200 mg / mL, wherein the salt provides a buffering capacity to maintain the pH of the solution between about pH 4.0 and about pH 8.0; and wherein the osmolality of the aqueous solution is about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the aqueous solution comprises water; a phosphate salt of imatinib at a concentration of about 0.001 mg / mL to about 200 mg / mL, wherein the salt provides a buffering capacity to maintain the pH of the solution between about pH 4.0 and about pH 8.0. In some embodiments, the water is replaced with saline.

[0011] In some embodiments, the aqueous solutions for nebulized inhalation administration described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation administration described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.01 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water, a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.01 mg / mL to about 50 mg / mL, about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions, and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water, a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.01 mg / mL to about 10 mg / mL, about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions, and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation administration described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.1 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.1 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and, optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.1 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and, optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.25% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.5% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solutions for nebulized inhalation administration described herein comprise water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.9% sodium chloride to adjust osmolality and provide osmotic ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.8% sodium chloride to adjust osmolality and provide osmotic ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.7% sodium chloride to adjust osmolality and provide osmotic ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 5.0 to about pH 8.0. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is a phenylaminopyrimidine derivative or a salt thereof. In some embodiments, the tyrosine kinase inhibitor or a salt thereof is imatinib or a salt thereof.

[0012] In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 40 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 30 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 20 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 1.0 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 2.0 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.25% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.5% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.9% sodium chloride to adjust osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.8% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.7% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 5.0 to about pH 8.0.

[0013] In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.01 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.01 mg / mL to about 50 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a compound of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 50 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust the molar osmolality and provide osmotic ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 10 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.25% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.5% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 0.9% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 0.8% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a compound of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 0.7% sodium hydrochloride to adjust the molar osmolality and provide osmotic ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide a permeant ion; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative that provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 7.0 is citrate. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; wherein the salt of imatinib or the salt of the phenylaminopyrimidine derivative, which provides buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0, is a phosphate.

[0014] In some embodiments, the present specification describes a unit dose suitable for use in a liquid nebulizer, comprising about 0.5 mL to about 6 mL of an aqueous solution of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, wherein the concentration of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof in the aqueous solution is about 0.1 mg / mL to about 100 mg / mL. In some embodiments, the present specification describes a unit dose suitable for use in a liquid nebulizer, comprising about 0.01 mL to about 6 mL of an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in the aqueous solution is about 0.001 mg / mL to about 200 mg / mL. In some embodiments, the aqueous solution further comprises one or more additional components selected from a cosolvent, a tonicity agent, a sweetener, a surfactant, a humectant, a chelating agent, an antioxidant, an inorganic salt, and a buffer; and the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the aqueous solution further comprises one or more inorganic salts selected from sodium chloride and magnesium chloride; and one or both of a citrate buffer and a phosphate buffer. In some embodiments, the aqueous solution comprises imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, dissolved in water at a concentration of about 0.5 mg / mL to about 50 mg / mL; optionally, sodium chloride to maintain the osmolality of the solution between 200 and 800 mOsmol / kg; optionally, a phosphate buffer to maintain the pH of the solution between 5.0 and 8.0; and optionally, a citrate buffer to maintain the pH of the solution between about pH 4.0 and about pH 7.0.In some embodiments, the aqueous solution comprises imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, dissolved in water at a concentration of about 0.001 mg / mL to about 200 mg / mL; optionally, sodium chloride to maintain the osmolality of the solution between 200 and 800 mOsmol / kg; optionally, a phosphate buffer to maintain the pH of the solution between 5.0 and 8.0; optionally, a citrate buffer to maintain the pH of the solution between about pH 4.0 and about pH 7.0; and optionally, a salt of imatinib or a salt of a phenylaminopyrimidine derivative, which itself maintains the pH of the solution between about pH 4.0 and about pH 8.0. In some embodiments, the aqueous solution is as described herein.

[0015] In some embodiments, the present disclosure provides a unit dose suitable for use in a liquid sprayer, comprising about 0.01 mL to about 6 mL of an aqueous solution of a tyrosine kinase inhibitor or a salt thereof, wherein the concentration of the tyrosine kinase inhibitor or a salt thereof in the aqueous solution is about 0.001 mg / mL to about 200 mg / mL. In some embodiments, the aqueous solution further comprises one or more additional components selected from a cosolvent, a tonicity agent, a sweetener, a surfactant, a humectant, a chelating agent, an antioxidant, an inorganic salt, and a buffer; and the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the aqueous solution further comprises one or more inorganic salts selected from sodium chloride and magnesium chloride; and one or both of a citrate buffer and a phosphate buffer. In some embodiments, the aqueous solution comprises a tyrosine kinase inhibitor or a salt thereof dissolved in water at a concentration of about 0.001 mg / mL to about 200 mg / mL; optionally, sodium chloride to maintain the osmolality of the solution between 200-800 mOsmol / kg; optionally, a phosphate buffer to maintain the pH of the solution between 5.0 and 8.0; optionally, a citrate buffer to maintain the pH of the solution between about pH 4.0 and about pH 7.0; and optionally, a salt of the tyrosine kinase inhibitor, which itself maintains the pH of the solution between about pH 4.0 and about pH 8.0. In some embodiments, the aqueous solution is as described herein.

[0016] In some embodiments, the present specification describes a kit that includes: a unit dose of an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, as described herein, in a container suitable for use in a liquid sprayer.

[0017] In some embodiments, the present specification provides imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the droplets have a diameter of less than about 5.0 μm. In some embodiments, the droplets are produced from a liquid atomizer and an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is as described herein. In some embodiments, the aqueous solution has a concentration of about 0.1 mg / mL to about 100 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the aqueous solution has a concentration of about 0.001 mg / mL to about 200 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the aqueous droplets are produced by spraying an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof as described herein with a liquid atomizer. In some embodiments, the atomizer is a liquid atomizer. In some embodiments, the atomizer is a high-performance liquid atomizer.

[0018] In some embodiments, provided herein is an aqueous aerosol comprising a plurality of droplets of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, provided herein is an aqueous aerosol comprising a plurality of droplets of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the plurality of droplets has a volume mean diameter (VMD), mass median aerodynamic diameter (MMAD), and / or mass median diameter (MMD) of less than about 5.0 μm. In some embodiments, the plurality of droplets is produced from a liquid nebulizer and an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the aqueous solution has a concentration of about 0.1 mg / mL to about 100 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, at least 30% of the water droplets in the aerosol have a diameter of less than about 5 μm. In some embodiments, the aqueous aerosol is produced by spraying an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, as described herein, using a liquid nebulizer. In some embodiments, the atomizer is a liquid atomizer. In some embodiments, the atomizer is a high performance liquid atomizer.

[0019] In some embodiments, the nebulizer used in any of the methods described herein is a liquid nebulizer. In some embodiments, the nebulizer used in any of the methods described herein is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer including a vibrating mesh or plate with multiple holes, or a nebulizer including a vibration generator and an aqueous chamber. In some embodiments, the nebulizer used in any of the methods described herein is a nebulizer including a vibrating mesh or plate with multiple holes. In some embodiments, the liquid nebulizer (i) achieves at least 7% lung deposition of the compound imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof administered to a mammal; (ii) provides a geometric standard deviation (GSD) of the diameter distribution of emitted droplets of an aqueous solution of about 1.0 μm to about 2.5 μm; (iii) provides a) a median aerodynamic diameter (MMAD) of the droplet size of the aqueous solution emitted from the high-performance liquid nebulizer of about 1 μm to about 5 μm; b) a volume mean diameter (VMD) of about 1 μm to about 5 μm; and / or c) a mass median diameter (MMD) of about 1 μm to about 5 μm; (iv) provides a fine particle fraction (FPF = %≦5 microns) of droplets emitted from the liquid nebulizer of at least about 30%; (v) provides a consumption rate of at least 0.1 mL / min; and / or (vi) provides at least about 25% aqueous solution to a mammal.

[0020] In some embodiments, the liquid nebulizer is characterized by having at least two, at least three, at least four, at least five, or all six of (i), (ii), (iii), (iv), (v), and (vi). In some embodiments, the liquid nebulizer (i) achieves lung deposition of at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 12%, at least 14%, at least 16%, at least 18%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof administered to a mammal. In some embodiments, the liquid atomizer provides (ii) a geometric standard deviation (GSD) of the droplet size distribution of the emitted droplets of the aqueous solution of about 1.0 μm to about 2.5 μm, about 1.2 μm to about 2.3 μm, about 1.4 μm to about 2.1 μm, or about 1.5 μm to about 2.0 μm. In some embodiments, the liquid atomizer provides (iii) a) a droplet size of the aqueous solution emitted by the high performance liquid atomizer of less than 5 μm, or about 1 μm to about 5 μm; b) a volume mean diameter (VMD) of less than about 5 μm, or about 1 μm to about 5 μm; and / or c) a mass median diameter (MMD) of less than about 5 μm, or about 1 μm to about 5 μm. In some embodiments, the liquid atomizer (iv) provides a fine particle fraction (FPF = %≦5 microns) of droplets emitted from the liquid atomizer of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90%.In some embodiments, the liquid nebulizer (v) provides a consumption rate of at least 0.1 mL / min, at least 0.2 mL / min, at least 0.3 mL / min, at least 0.4 mL / min, at least 0.5 mL / min, at least 0.6 mL / min, at least 0.7 mL / min, at least 0.8 mL / min, at least 0.9 mL / min, at least 1.0 mL / min, or less than about 1.0 mL / min. In some embodiments, the liquid nebulizer (vi) provides to a mammal at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 95% aqueous solution. In some embodiments, the liquid nebulizer provides a respirable delivered dose (RDD) of at least 5%, at least 6%, at least 7%, at least 8%, at least 10%, at least 12%, at least 16%, at least 20%, at least 24%, at least 28%, at least 32%, at least 36%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90%.

[0021] In some embodiments, the present specification describes a method for treating a pulmonary disease in a mammal, the method comprising administering by inhalation to a mammal in need thereof a pharmaceutical composition comprising a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the pulmonary disease is pulmonary fibrosis, lung cancer, or pulmonary arterial hypertension, and the mammal is a human. In some embodiments, the pharmaceutical composition comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or a tyrosine kinase inhibitor or a salt thereof is administered by a nebulizer, a metered dose inhaler, or a dry powder inhaler. In some embodiments, the pharmaceutical composition comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or a tyrosine kinase inhibitor or a salt thereof is an aqueous solution and is administered to a mammal by a liquid nebulizer; wherein the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the liquid nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer comprising a vibrating mesh or plate with multiple holes, or a nebulizer comprising a vibration generator and an aqueous chamber.In some embodiments, the liquid nebulizer (i) achieves a lung deposition of at least 7% of imatinib or its salt, phenylaminopyrimidine derivative or salt, or other tyrosine kinase inhibitor or its salt administered to a mammal; (ii) provides a geometric standard deviation (GSD) of the emitted droplet size distribution of an aqueous solution of about 1.0 μm to about 2.5 μm; (iii) provides a) a median aerodynamic diameter (MMAD) of the droplet size of the aqueous solution emitted from the high-performance liquid nebulizer of about 1 μm to about 5 μm; b) a volume mean diameter (VMD) of about 1 μm to about 5 μm; and / or c) a mass median diameter (MMD) of about 1 μm to about 5 μm; (iv) provides a fine particle fraction (FPF = %≦5 microns) of droplets emitted from the liquid nebulizer of at least about 30%; (v) provides a consumption rate of at least 0.1 mL / min; and / or (vi) provides at least about 25% aqueous solution to a mammal. In some embodiments, the liquid nebulizer delivers about 0.001 mg to about 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof compound to the lungs of a mammal in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the pharmaceutical composition comprises an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or a tyrosine kinase inhibitor or a salt thereof compound, wherein the pharmaceutical composition is administered to a mammal by the liquid nebulizer. In some embodiments, the pharmaceutical composition comprises about 0.1 mL to about 6 mL of an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative compound or a salt thereof, or a tyrosine kinase inhibitor compound or a salt thereof, and optionally one or more additional components selected from cosolvents, isotonicity agents, sweeteners, surfactants, humectants, chelating agents, antioxidants, inorganic salts, and buffers, wherein the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or a tyrosine kinase inhibitor compound or a salt thereof in the aqueous solution is about 0.001 mg / mL to about 200 mg / mL, and the molar osmolarity of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg.In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative compound or a salt thereof, or another tyrosine kinase inhibitor compound or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; optionally, one or more inorganic salts selected from the group consisting of sodium chloride, magnesium chloride, sodium bromide, magnesium bromide, calcium chloride, and calcium bromide, wherein the total amount of the one or more inorganic salts is about 0.01% to about 2.0% by weight of the aqueous solution; and optionally, a phosphate buffer that maintains the pH of the solution at about pH 5.0 to about pH 8.0, or a citrate buffer that maintains the pH of the solution at about 4.0 to about 7.0; optionally, sodium saccharin at a concentration of about 0.01 mM to about 10 mM; wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the pharmaceutical composition comprises a dry powder composition comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001% to about 100% by weight of the dry powder composition; optionally, one or more carrier agents selected from the group consisting of lactose or mannitol, at a concentration of about 0.001% to about 99.999% by weight of the dry powder composition; and optionally, sodium saccharin, at a concentration of about 0.001% to about 0.1% by weight of the dry powder composition; wherein the pharmaceutical composition is administered to a mammal via a dry powder inhaler. In some embodiments, the dry powder nebulizer delivers about 0.001 mg to about 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the lungs of a mammal in less than 10 breaths, wherein the particle size in mass median diameter (MMAD) is about 1 to about 5 microns.In some embodiments, the pharmaceutical composition comprises imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof (wherein the total amount of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is about 0.001% to about 10% by volume of the pharmaceutical composition); one or more propellants (wherein the total amount of the one or more propellants is about 90% to about 99.999% by volume of the pharmaceutical composition); and optionally, one or more cosolvents selected from the group consisting of ethanol and propylene glycol (wherein the total amount of the one or more cosolvents is about 0.01% to about 10% by volume of the pharmaceutical composition); wherein the pharmaceutical composition is administered to a mammal via a metered dose inhaler. In some embodiments, a metered dose nebulizer delivers about 0.001 mg to about 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the lungs of a mammal in fewer than 10 breaths, wherein the particle size in mass median diameter (MMAD) is about 1 to about 5 microns. In some embodiments, a pharmaceutical composition comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered to a mammal in need thereof by inhalation on a continuous dosing schedule. In some embodiments, a pharmaceutical composition comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered once a week, twice a week, three times a week, four times a week, five times a week, six times a week, seven times a week, once a day, twice a day, three times a day, four times a day, five times a day, or six times a day.

[0022] In some embodiments, the present specification describes a method for treating pulmonary diseases in a mammal, the method comprising: administering an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a mammal in need thereof via a liquid nebulizer. In some embodiments, the present specification describes a method for treating pulmonary diseases in a mammal, the method comprising: administering imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof to a mammal in need thereof via a liquid nebulizer, wherein the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof at a concentration of about 0.1 mg / mL to about 100 mg / mL; one or more inorganic salts, wherein the aqueous solution has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg; and one or more buffering agents that maintain the pH of the solution between about 4.0 and 8.0. In some embodiments, the present specification describes a method for treating pulmonary diseases in a mammal, the method comprising: administering an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a mammal in need thereof via a liquid nebulizer; wherein the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; one or more salts, wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg; and one or more buffering agents that maintain the pH of the solution between about 4.0 and 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.25% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.5% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.9% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.8% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.7% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 5.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide osmotic ions; wherein the salt providing buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 7.0 is citrate. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide osmotic ions; wherein the salt providing buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0 is a phosphate.

[0023] In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 30 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 20 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.25% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.25% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.5% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.5% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.9% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.9% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.8% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.8% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.7% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 0.7% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a phosphate buffer or citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust the osmolality and provide osmotic ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.5 mg / mL to about 50 mg / mL; and about 0.1% to about 1.0% hydrochloric acid to adjust osmolality and provide permeant ions. sodium; and optionally a phosphate buffer that maintains the pH of the solution at about pH 5.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally a phosphate buffer that maintains the pH of the solution at about pH 5.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide osmotic ions; wherein the salt providing buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 7.0 is citrate. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide a permeable ion; wherein the salt providing buffering capacity to maintain the pH of the solution at about pH 4.0 to about pH 8.0 is a phosphate salt. In some embodiments, the nebulizer is a jet nebulizer, an ultrasonic nebulizer, a pulsating membrane nebulizer, a nebulizer including a vibrating mesh or plate with multiple holes, or a nebulizer including a vibration generator and an aqueous chamber.In some embodiments, the liquid nebulizer (i) achieves a lung deposition of at least 7% of imatinib or its salt, phenylaminopyrimidine derivative or salt, or other tyrosine kinase inhibitor or its salt administered to a mammal; (ii) provides a geometric standard deviation (GSD) of the emitted droplet size distribution of an aqueous solution of about 1.0 μm to about 2.5 μm; (iii) provides a) a median aerodynamic diameter (MMAD) of the droplet size of the aqueous solution emitted from the high-performance liquid nebulizer of about 1 μm to about 5 μm; b) a volume mean diameter (VMD) of about 1 μm to about 5 μm; and / or c) a mass median diameter (MMD) of about 1 μm to about 5 μm; (iv) provides a fine particle fraction (FPF = %≦5 microns) of droplets emitted from the liquid nebulizer of at least about 30%; (v) provides a consumption rate of at least 0.1 mL / min; and / or (vi) provides at least about 25% aqueous solution to a mammal. In some embodiments, the mammal is a human. In some embodiments, the pulmonary disease is pulmonary fibrosis, and the mammal is a human. In some embodiments, the pulmonary disease is idiopathic pulmonary fibrosis, and the mammal is a human. In some embodiments, the pulmonary disease is pulmonary arterial hypertension, and the mammal is a human. In some embodiments, the pulmonary disease is type 1, type 2, type 3, type 4, or type 5 pulmonary arterial hypertension, and the mammal is a human. In some embodiments, the pulmonary disease is cancer, and the mammal is a human. In some embodiments, the lung cancer is small cell lung cancer, and the mammal is a human. In some embodiments, the lung cancer is non-small cell lung cancer, and the mammal is a human. In some embodiments, the lung cancer is large cell carcinoma, and the mammal is a human. In some embodiments, the lung cancer is mesothelioma, and the mammal is a human. In some embodiments, the lung cancer is pulmonary carcinoid tumor or bronchial carcinoid, and the mammal is a human. In some embodiments, the lung cancer is secondary lung cancer resulting from metastatic disease, and the mammal is a human. In some embodiments, the lung cancer is bronchioloalveolar carcinoma and the mammal is a human. In some embodiments, the lung cancer can be a sarcoma and the mammal is a human. In some embodiments, the lung cancer can be a lymphoma and the mammal is a human.In some embodiments, the liquid nebulizer delivers about 0.05 mg to about 600 mg of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, to the lungs of a mammal in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the liquid nebulizer delivers about 0.01 mg to about 600 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, to the lungs of a mammal in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD).

[0024] In some embodiments, the Cmax and / or AUC in the lung tissue of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after administration of a single inhaled dose to a mammal is approximately the same as, or is equal to, the Cmax and / or AUC in the lung tissue of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after oral administration of a single dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof, at a dose of about 80% to about 120% of the inhaled dose. or greater; and / or the plasma Cmax and / or AUC of imatinib or its salt, a phenylaminopyrimidine derivative or its salt, or other tyrosine kinase inhibitor or its salt obtained after administration of a single inhaled dose to a mammal is less than the plasma Cmax and / or AUC of imatinib or its salt, a phenylaminopyrimidine derivative or its salt, or other tyrosine kinase inhibitor or its salt obtained after oral administration of a single dose of imatinib or its salt, a phenylaminopyrimidine derivative or its salt, or other tyrosine kinase inhibitor or its salt, at a dose of about 80% to about 120% of the inhaled dose. In some embodiments, the Cmax of pulmonary tissue of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after administration of a single inhaled dose to a mammal is greater than the Cmax of pulmonary tissue of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after oral administration of a single dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof, at a dose of about 80% to about 120% of the inhaled dose.In some embodiments, the AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof in the lung tissue obtained after administration of a single inhaled dose to a mammal is greater than the AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof in the lung tissue obtained after oral administration of a single dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof at a dose of about 80% to about 120% of the inhaled dose. In some embodiments, the plasma Cmax of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after administration of a single inhaled dose to a mammal is less than the plasma Cmax of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof obtained after oral administration of a single dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof, at a dose of about 80% to about 120% of the inhaled dose. In some embodiments, the plasma AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof obtained after administration of a single inhaled dose to a mammal is less than the plasma AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof obtained after oral administration of a single dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a dose that is about 80% to about 120% of the inhaled dose.

[0025] In some embodiments, the liquid nebulizer delivers about 0.1 mg to about 600 mg of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, to the lungs of a mammal in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the liquid nebulizer delivers about 0.01 mg to about 600 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the lungs of a mammal in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD).

[0026] In some embodiments, administration by liquid nebulizer does not include an initial dose escalation period.

[0027] In some embodiments, the present specification describes a method for reducing the risk of gastrointestinal (GI) adverse events in treatment of a human with imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, the method comprising administering, via a liquid nebulizer, an atomized aqueous solution comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human in need thereof; wherein: The aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.1 mg / mL to about 100 mg / mL; one or more inorganic salts, wherein the osmolality of the aqueous solution is about 50 mOsmol / kg to about 2000 mOsmol / kg; and one or more buffers that maintain the pH of the solution between about 4.0 and 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 40 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 50 mg / mL, or about 0.5 mg / mL to about 30 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.01 mg / mL to about 10 mg / mL, or about 0.5 mg / mL to about 20 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 200 mg / mL, or about 1.0 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 50 mg / mL, or about 2.0 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.1 mg / mL to about 10 mg / mL, or about 5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.25% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.5% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.9% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.8% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 0.7% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer, a citrate buffer, or a salt of a tyrosine kinase inhibitor, which itself maintains the pH of the solution at about pH 4.0 to about pH 8.0.In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium chloride to adjust osmolality and provide permeant ions; and optionally, a citrate buffer to maintain the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.5 mg / mL to about 50 mg / mL; about 0.1% to about 1.0% sodium hydrochloride to adjust osmolality and provide permeant ions; and optionally, a phosphate buffer to maintain the pH of the solution at about pH 5.0 to about pH 8.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust the osmolality and provide a permeant ion; wherein the citrate salt maintains the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution for nebulized inhalation administration described herein comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and about 0.1% to about 1.0% sodium hydrochloride to adjust the osmolality and provide a permeant ion; wherein the phosphate salt maintains the pH of the solution at about pH 5.0 to about pH 8.0.In some embodiments, the aqueous solution comprises water; a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL, or about 0.1 mg / mL to about 100 mg / mL; one or more inorganic salts, wherein the aqueous solution has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg; and one or more buffering agents that maintain the pH of the solution between about 4.0 and 8.0. In some embodiments, imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered to treat a human lung disease. In some embodiments, the lung disease is idiopathic pulmonary fibrosis. In other embodiments, the lung disease is cancer. In some embodiments, the lung disease target is stroma associated with lung cancer. In some embodiments, the lung disease is pulmonary hypertension.

[0028] In some embodiments, the liquid nebulizer delivers about 0.1 mg to about 600 mg of imatinib or a phenylaminopyrimidine derivative compound to the lungs in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the liquid nebulizer delivers about 0.01 mg to about 600 mg of imatinib or a phenylaminopyrimidine derivative, or a tyrosine kinase inhibitor compound to the lungs in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD).

[0029] In some embodiments, administration by liquid nebulizer does not include an initial dose escalation period.

[0030] In some embodiments, about 0.5 mL to about 6 mL of an aqueous solution is administered to a mammal by a liquid nebulizer, the solution having imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 100 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg; and the liquid nebulizer is a nebulizer including a vibrating mesh or plate with multiple holes. In some embodiments, about 0.01 mL to about 6 mL of an aqueous solution is administered to a mammal by a liquid nebulizer, the solution having imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg; and the liquid nebulizer is a nebulizer including a vibrating mesh or plate with multiple holes.

[0031] In some embodiments, the liquid nebulizer delivers about 0.1 mg to about 600 mg of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof to the lungs in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the aqueous solution has a pH of about 4.0 to about 8.0 and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the liquid nebulizer delivers about 0.01 mg to about 600 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the lungs in less than 20 minutes with a particle size of about 1 to about 5 microns mass median diameter (MMAD). In some embodiments, the aqueous solution has a pH of about 4.0 to about 8.0 and an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg.

[0032] In some embodiments, the present specification describes an inhalation system for administering a compound, such as imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, to the respiratory system of a human, the system comprising: (a) about 0.5 mL to about 6 mL of an aqueous solution of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof; and (b) a high-performance liquid nebulizer. In some embodiments, the present specification describes an inhalation system for administering a compound, such as imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, to the respiratory system of a human, the system comprising: (a) about 0.01 mL to about 6 mL of an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof; and (b) a high-performance liquid nebulizer. In some embodiments, the aqueous solution is any of the aqueous solutions described herein. In some embodiments, the concentration of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof in the aqueous solution is about 0.1 mg / mL to about 100 mg / mL, and the osmolality of the aqueous solution is about 200 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in the aqueous solution is about 0.001 mg / mL to about 200 mg / mL, and the osmolality of the aqueous solution is about 200 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof at a concentration of about 0.1 mg / mL to about 50 mg / mL; and optionally a phosphate buffer that maintains the pH of the solution at about pH 5.0 to about pH 8.0. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and optionally, a phosphate buffer that maintains the pH of the solution at about pH 5.0 to about pH 8.0.In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, at a concentration of about 0.1 mg / mL to about 50 mg / mL; and optionally a citrate buffer that maintains the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; and optionally a citrate buffer that maintains the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; wherein the phosphate maintains the pH of the solution at about pH 4.0 to about pH 8.0. In some embodiments, the aqueous solution comprises water; imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration of about 0.001 mg / mL to about 200 mg / mL; wherein the citrate salt maintains the pH of the solution at about pH 4.0 to about pH 7.0. In some embodiments, the aqueous solution is as described herein.

[0033] In one aspect, the present specification describes a method for achieving a Cmax in lung tissue of a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the Cmax is at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 1.5 ... 0.5 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 1.5-20 times, at least 1.5-15 times, at least 1.5-10 times, at least 1.5-5 times, or at least 1.5-3 times, and the method includes the steps of nebulizing an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and administering the nebulized aqueous solution to a human. In some embodiments, the present specification describes a method for achieving a Cmax in lung tissue of a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the Cmax is at least equal to or greater than the Cmax of up to about 600 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, the method comprising the steps of nebulizing an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and administering the nebulized aqueous solution to a human.

[0034] In one aspect, the present specification provides a method for measuring the AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in lung tissue. 0-24 A method for achieving AUC is described. 0-24 is the AUC of imatinib or its salt, phenylaminopyrimidine derivatives or their salts, or other tyrosine kinase inhibitors or their salts at oral doses up to 600 mg.0-24 and the AUC of the lung tissue of a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 1.5-fold, at least 1.5-fold, at least 1.5-fold, at least 1.5-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold, at least 1.5-20-fold, at least 1.5-15-fold, at least 1.5-10-fold, at least 1.5-5-fold, or at least 1.5-3-fold of the AUC of the lung tissue of a compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and the method comprises the steps of nebulizing an aqueous solution containing the compound of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and administering the nebulized aqueous solution to a human. 0-24 A method for achieving AUC is described. 0-24 is the AUC of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof up to about 600 mg. 0-24 The method comprises the steps of nebulizing an aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and administering the nebulized aqueous solution to a human.

[0035] In one aspect, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the Cmax of the lung tissue achieved by the nebulized solution is lower than that of orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. The Cmax of the lung tissue is at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 1.5-20 times, at least 1.5-15 times, at least 1.5-10 times, at least 1.5-5 times, or at least 1.5-3 times that achieved by the salt, and the dose is 80% to 120% of the dose of imatinib administered by nebulization.

[0036] In one aspect, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising the step of administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the Cmax of the lung tissue achieved by the nebulized solution is at least 1.5 times less than the Cmax of the lung tissue achieved by orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. The dose is at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 1.5-20 times, at least 1.5-15 times, at least 1.5-10 times, at least 1.5-5 times, or at least 1.5-3 times, and the dose is 80% to 120% of the dose of imatinib administered by nebulization in an nebulized aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In one embodiment, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising the step of administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the Cmax of the lung tissue achieved by the nebulized solution is at least equal to or greater than the Cmax of the lung tissue achieved by orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and the dosage is 80% to 120% of the dosage of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in the administered nebulized aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.

[0037] In some embodiments, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the plasma AUC 0-24 is the plasma AUC achieved by orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. 0-24 The dosage is less than 80% to 120% of the dosage of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in the administered spray aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.

[0038] In one aspect, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the AUC of the lung tissue achieved by the nebulized solution is 0-24 is the AUC of lung tissue achieved by orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. 0-24 the dose is at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 1.5 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 1.5-20 times, at least 1.5-15 times, at least 1.5-10 times, at least 1.5-5 times, or at least 1.5-3 times the dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in an atomized aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and the dose is 80% to 120% of the dose of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the present specification describes a method for administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to a human, the method comprising administering an nebulized aqueous solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the AUC of the lung tissue achieved by the nebulized solution is 0-24 is the AUC of lung tissue achieved by orally administered imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. 0-24is at least 1.5 times the dose, and the dosage is 80% to 120% of the dose of imatinib or its salt, phenylaminopyrimidine derivative or its salt, or other tyrosine kinase inhibitor or its salt in an nebulized aqueous solution of imatinib or its salt, phenylaminopyrimidine derivative or its salt, or other tyrosine kinase inhibitor or its salt.

[0039] In one aspect, provided herein is a method for improving the pharmacokinetic profile obtained from a human after a single oral administration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered to a human to treat a lung disease. In some embodiments, the lung disease is pulmonary fibrosis. In some embodiments, the lung disease is idiopathic pulmonary fibrosis. In some embodiments, a single oral dose contains up to about 600 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the method for improving the pharmacokinetic profile comprises administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof by inhalation. In some embodiments, the pharmacokinetic profile comprises a pulmonary tissue pharmacokinetic profile. In some embodiments, the pharmacokinetic profile includes a pulmonary tissue pharmacokinetic profile and / or a plasma pharmacokinetic profile. In some embodiments, imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered as an aqueous solution via a liquid nebulizer. In some embodiments, the aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is as described herein. In some embodiments, the method for improving the pharmacokinetic profile further includes comparing the pharmacokinetic parameters obtained after inhalation administration with the pharmacokinetic parameters obtained after oral administration. In some embodiments, a long-term improvement in the pharmacokinetic profile is obtained by repeated and frequent administration of an aqueous solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof as described herein via inhalation.In some embodiments, repeated administration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof by inhalation provides more frequent direct lung exposure, benefiting humans through repeated high Cmax levels. In some embodiments, the dose of inhaled imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered once daily, twice daily, three times daily, four times daily, every other day, twice weekly, three times weekly, four times weekly, five times weekly, six times weekly, seven times weekly, or any combination thereof.

[0040] In some embodiments, the present specification describes a pharmaceutical composition for pulmonary delivery, the pharmaceutical composition comprising an aqueous solution of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, the aqueous solution having a concentration greater than about 0.1 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the present specification describes a pharmaceutical composition for pulmonary delivery, the pharmaceutical composition comprising a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, the solution having a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 200.0 mg / mL. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the composition comprises a taste-masking agent.In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the composition comprises a mucolytic agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery.

[0041] In some embodiments, the present specification describes a pharmaceutical composition for pulmonary delivery, comprising a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and a taste-masking agent, wherein the solution has an osmolality greater than about 100 mOsmol / kg and a pH greater than about 4.0. In some embodiments, the imatinib or a salt thereof, the phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, the phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 200.0 mg / mL. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the composition comprises a taste-masking agent.In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the composition comprises a mucolytic agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery.

[0042] In some embodiments, the present specification describes a single-use sterile container containing about 0.1 mL to about 20 mL of a solution comprising imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, and having a concentration greater than about 0.1 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the present specification describes a single-use sterile container containing about 0.01 mL to about 20 mL of a solution comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and having a concentration greater than about 0.001 mg / mL, an osmolality greater than about 200 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.001 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL, hi some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 200.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg.In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the container further comprises a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the container further comprises administering a mucolytic agent suitable for pulmonary delivery. In some embodiments, the container further comprises a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition includes a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery.

[0043] In some embodiments, the present specification describes a method for treating a pulmonary disease, the method comprising inhaling an aerosol generated from a solution containing imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, wherein the solution has a concentration greater than about 0.1 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the present specification describes a method for treating a pulmonary disease, the method comprising inhaling an aerosol generated from a solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the solution has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 200.0 mg / mL. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent.In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the pulmonary disease is interstitial lung disease. In some embodiments, the interstitial lung disease is idiopathic pulmonary fibrosis. In some embodiments, the interstitial lung disease is radiation therapy-induced pulmonary fibrosis. In some embodiments, the lung disease is chronic obstructive pulmonary disease. In some embodiments, the lung disease is chronic bronchitis. In some embodiments, the lung disease is cancer. In some embodiments, the lung cancer is small cell lung cancer. In some embodiments, the lung cancer is large cell carcinoma. In some embodiments, the lung cancer is mesothelioma. In some embodiments, the lung cancer is pulmonary carcinoid tumor or bronchial carcinoid. In some embodiments, the lung cancer is secondary lung cancer resulting from metastatic disease. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the lung cancer is bronchioloalveolar carcinoma. In some embodiments, the lung cancer can be a sarcoma. In some embodiments, the lung cancer can be a lymphoma. In some embodiments, the method further includes co-administering, sequentially administering, or co-prescribing (such as when a prescribing physician requires several drugs to be taken in sequence as a combination therapy to treat the same disease) a taste-masking agent.In some embodiments, imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is administered to the stroma associated with the target cancer to reduce cancer cell proliferation, invasion, and metastasis, allow anticancer drugs to penetrate cancer cells, and reduce interfering hypertension (thereby increasing access of anticancer drugs to internal cancer cells). In some embodiments, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns. In some embodiments, the aerosol has a mean particle size in volumetric mean diameter of about 1 micron to about 5 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the inhalation step delivers a dose of at least 5 mcg of imatinib or a salt thereof, or a phenylaminopyrimidine or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.001 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or or other tyrosine kinase inhibitor or salt thereof. In some embodiments, the inhalation step delivers a dose of at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or other tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhaling step delivers a dose of at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 250 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step is performed in less than about 20 minutes. In some embodiments, the inhaling step is performed in less than about 10 minutes. In some embodiments, the inhaling step is performed in less than about 7.5 minutes. In some embodiments, the inhaling step is performed in less than about 5 minutes. In some embodiments, the inhaling step is performed in less than about 2.5 minutes. In some embodiments, the inhaling step is performed in less than about 1.5 minutes. In some embodiments, the inhaling step is performed in less than about 30 seconds. In some embodiments, the inhaling step is performed within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within less than about 1 breath.

[0044] In some embodiments, the present specification describes a method for treating a pulmonary disease, the method comprising inhaling an aerosol generated from a solution containing imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, wherein the solution has a concentration greater than about 0.1 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the present specification describes a method for treating a pulmonary disease, the method comprising inhaling an aerosol generated from a solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the solution has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent.In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition comprises a second anti-pulmonary arterial hypertension agent suitable for pulmonary delivery. In some embodiments, the pulmonary disease is interstitial lung disease. In some embodiments, the interstitial lung disease is idiopathic pulmonary fibrosis. In some embodiments, the interstitial lung disease is radiation therapy-induced pulmonary fibrosis. In some embodiments, the pulmonary disease is chronic obstructive pulmonary disease. In some embodiments, the pulmonary disease is chronic bronchitis. In some embodiments, the pulmonary disease is pulmonary hypertension. In some embodiments, the pulmonary hypertension is type 1. In some embodiments, the pulmonary hypertension is type 2. In some embodiments, the pulmonary hypertension is type 3. In some embodiments, the pulmonary hypertension is type 4. In some embodiments, the pulmonary hypertension is type 5. In some embodiments, the pulmonary hypertension is associated with pulmonary fibrosis. In some embodiments, the method further comprises co-administering, sequentially administering, or co-prescribing with an agent targeting pulmonary hypertension (such that a prescribing physician requires drugs to be taken in sequence as a combination therapy to treat the same disease). In some embodiments, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns.In some embodiments, the aerosol has a mean particle size of about 1 micron to about 5 microns in volumetric mean diameter and a geometric standard deviation of 3 microns or less. In some embodiments, the inhalation step delivers a dose of at least 0.001 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 130 mg. In some embodiments, the inhalation step delivers a dose of at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 250 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step is performed in less than about 20 minutes. In some embodiments, the inhalation step is performed in less than about 10 minutes. In some embodiments, the inhaling step occurs in less than about 7.5 minutes, in some embodiments, the inhaling step occurs in less than about 5 minutes, and in some embodiments, the inhaling step occurs in less than about 2.5 minutes.In some embodiments, the inhaling step occurs within less than about 1.5 minutes. In some embodiments, the inhaling step occurs within less than about 30 seconds. In some embodiments, the inhaling step occurs within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within less than about 1 breath.

[0045] In one aspect, the present specification describes a method for administering an anti-fibrotic agent to a patient's lungs, the method comprising introducing a solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof into a nebulizer, the solution having a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for pulmonary delivery.In some embodiments, the mucolytic agent is inhaled separately from a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the method further comprises administering a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery.

[0046] In one aspect, the present specification describes a method for treating an extrapulmonary disease target, comprising inhaling an aerosol generated from a solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the solution has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for pulmonary delivery.In some embodiments, the mucolytic agent is inhaled separately from a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the method further comprises administering a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the method further comprises administering a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the extrapulmonary disease target is the heart. In some embodiments, the extrapulmonary disease target is a white blood cell. In some embodiments, the extrapulmonary disease target is the bone marrow. In some embodiments, the extrapulmonary disease target is the kidney. In some embodiments, the extrapulmonary disease target is the liver. In some embodiments, the extrapulmonary disease target is the central nervous system. In some embodiments, the composition may be co-administered with a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery.

[0047] In any of the methods described herein that use an aerosol or nebulizer to deliver a compound, such as imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, to the lungs, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns. In some embodiments, the aerosol has a mean particle size in volumetric mean diameter of about 1 micron to about 5 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the inhaling step delivers a dose of at least 5 mcg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 0.001 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 250 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step occurs in less than about 20 minutes. In some embodiments, the inhaling step occurs in less than about 10 minutes. In some embodiments, the inhaling step occurs in less than about 7.5 minutes. In some embodiments, the inhaling step occurs in less than about 5 minutes. In some embodiments, the inhaling step occurs in less than about 2.5 minutes. In some embodiments, the inhaling step occurs in less than about 1.5 minutes. In some embodiments, the inhaling step occurs in less than about 30 seconds. In some embodiments, the inhaling step occurs within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within less than about 1 breath.

[0048] In one aspect, the present specification describes a method for treating a neurological disease, comprising nasal inhalation of an aerosol generated from a solution containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the solution has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for pulmonary delivery.In some embodiments, the mucolytic agent is inhaled separately from a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.

[0049] In some embodiments, the present specification describes a method for administering an anti-demylination agent to the nasal cavity of a patient, the method comprising introducing a solution having imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof into a nebulizer, the solution having a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the method further comprises administering a mucolytic agent suitable for nasal delivery.In some embodiments, the mucolytic agent is inhaled separately from the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the method further comprises administering a second agent suitable for nasal delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic agent, anti-cancer agent, or anti-infective agent suitable for nasal delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for nasal delivery.

[0050] In any of the methods described herein that include a step of introducing a solution of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof into a nebulizer, the method includes a step of opening a disposable sterile container containing between about 0.5 mL and about 10 mL of a solution of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, for introduction into the nebulizer.

[0051] In any of the methods described herein that include a step of introducing a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof into a nebulizer, the method includes a step of opening a disposable sterile container containing between about 0.01 mL and about 10 mL of a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for introduction into the nebulizer.

[0052] In any of the methods described herein that involve a nebulizer, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns. In some embodiments, the aerosol has a mean particle size volumetric mean diameter of about 1 micron to about 5 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 20 microns. In some embodiments, the aerosol has a mean particle size volumetric mean diameter of about 1 micron to about 20 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the inhaling step delivers a dose of at least 5 mcg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 0.001 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 250 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step is performed in less than about 20 minutes. In some embodiments, the inhaling step is performed in less than about 10 minutes. In some embodiments, the inhaling step is performed in less than about 7.5 minutes. In some embodiments, the inhaling step is performed in less than about 5 minutes. In some embodiments, the inhaling step is performed in less than about 2.5 minutes. In some embodiments, the inhaling step is performed in less than about 1.5 minutes. In some embodiments, the inhaling step is performed in less than about 30 seconds. In some embodiments, the inhaling step is performed within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within less than about 1 breath.

[0053] In one aspect, the present specification describes a kit comprising: a pharmaceutical composition containing a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in a sterile container, wherein the solution has an imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof is greater than about 12.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate. In some embodiments, the kit further comprises a mucolytic agent suitable for pulmonary delivery. In some embodiments, the kit further comprises a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery.In some embodiments, the kit further comprises a second anti-inflammatory agent suitable for pulmonary delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery.

[0054] In another aspect, the present specification describes a kit comprising: a pharmaceutical composition containing a solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in a sterile container, wherein the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a concentration greater than 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0; and a nebulizer adapted to aerosolize the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for delivery to the nasal cavity via nasal inhalation.

[0055] In some embodiments, the solution contains imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, at a concentration greater than about 0.1 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a concentration greater than about 0.001 mg / mL, an osmolality greater than about 100 mOsmol / kg, and a pH greater than about 4.0. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.01 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.1 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 0.5 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 1.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 2.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 4.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 8.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof is greater than about 12.0 mg / mL.In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 16.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 20.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 50.0 mg / mL. In some embodiments, the concentration of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than about 100.0 mg / mL. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a permeant ion concentration of about 30 mM to about 300 mM. In some embodiments, the permeant ion is chloride or bromide. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has a pH of about 4.0 to about 8.0. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 100 mOsmol / kg to about 1000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof has an osmolality of about 50 mOsmol / kg to about 2000 mOsmol / kg. In some embodiments, the solution of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof contains a taste-masking agent. In some embodiments, the taste-masking agent is selected from the group consisting of lactose, sucrose, dextrose, saccharin, aspartame, sucralose, ascorbate, and citrate.In some embodiments, the kit further comprises a mucolytic agent suitable for nasal delivery. In some embodiments, the kit further comprises a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for nasal delivery. In some embodiments, the kit further comprises a second anti-inflammatory agent suitable for nasal delivery. In some embodiments, the composition may be co-administered with a second anti-fibrotic, anti-cancer, or anti-infective agent suitable for pulmonary delivery. In some embodiments, the composition is co-administered with a second anti-inflammatory agent suitable for pulmonary delivery.

[0056] In one aspect, the present specification describes a method for treating a pulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having interstitial lung disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the disease is selected from interstitial lung diseases, including idiopathic pulmonary fibrosis and radiation therapy-induced fibrosis. In some embodiments, the subject is identified as having interstitial lung disease. In some embodiments, the subject is identified as having idiopathic pulmonary fibrosis. In some embodiments, the subject is identified as having radiation therapy-induced pulmonary fibrosis. In some embodiments, the subject is a subject on a ventilator.

[0057] In one aspect, the present specification describes a method for treating a lung disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an interstitial lung disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the disease is selected from interstitial lung diseases, including pulmonary hypertension. In some embodiments, the subject is confirmed to have an interstitial lung disease. In some embodiments, the subject is confirmed to have pulmonary hypertension. In some embodiments, the subject is confirmed to have portopulmonary hypertension. In some embodiments, the subject is a subject on a ventilator.

[0058] In one aspect, the present specification describes a method for treating a pulmonary disease, comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having a pulmonary disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the pulmonary disease is cancer. In some embodiments, the lung cancer is small cell lung cancer. In some embodiments, the lung cancer is large cell carcinoma. In some embodiments, the lung cancer is mesothelioma. In some embodiments, the lung cancer is pulmonary carcinoid tumor or bronchial carcinoid. In some embodiments, the lung cancer is secondary lung cancer resulting from metastatic disease. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the lung cancer is bronchioloalveolar carcinoma. In some embodiments, the lung cancer may be a sarcoma. In some embodiments, the lung cancer can be lymphoma. In some embodiments, the subject is a mechanically ventilated subject.

[0059] In one aspect, the present specification describes a method for treating pulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having pulmonary disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the pulmonary disease is cancer. In some embodiments, the therapeutic target of the lung cancer is tumor stroma. In some embodiments, the subject is a subject on a ventilator.

[0060] In one aspect, the present specification describes a method for treating a pulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having a pulmonary disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the pulmonary disease is pulmonary hypertension. In some embodiments, the subject is a subject on a ventilator.

[0061] A method for treating an extrapulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an extrapulmonary cancer via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the disease is selected from localized cancers including leukemia and lymphoma. In some embodiments, the subject is confirmed to have chronic myeloid leukemia (CML). In some embodiments, the subject is confirmed to have gastrointestinal stromal tumor (GIST). In some embodiments, the subject is confirmed to have relapsed or refractory Ph-positive acute lymphoblastic leukemia (ALL). In some embodiments, the subject is confirmed to have a myelodysplastic / myeloproliferative disorder associated with rearrangements of the platelet-derived growth factor receptor gene. In some embodiments, the subject is identified as having aggressive systemic mastocytosis (ASM) with or without an unknown D816V c-KIT mutation. In some embodiments, the subject is a mechanically ventilated subject. In some embodiments, the subject is identified as having hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL), and the subject has FIP1L1-PDGFRα fusion kinase (CHIC2 allele deletion) or a negative or unknown FIP1L1-PDGFR-alpha fusion kinase. In some embodiments, the subject is identified as having unresectable, recurrent, and / or metastatic dermatofibrosarcoma protuberans.

[0062] A method for treating an extrapulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof via oral inhalation of an aerosol comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having a disease associated with extrapulmonary fibrosis, inflammation, and / or toxicity, for pulmonary vascular absorption and delivery to the affected tissue outside the lung, wherein the disease is selected from cardiac fibrosis, renal fibrosis, hepatic fibrosis, nephrotoxicity, and cardiac toxicity. In some embodiments, the subject is identified as suffering from cardiac fibrosis. In some embodiments, the subject is identified as suffering from renal fibrosis. In some embodiments, the subject is identified as suffering from hepatic fibrosis. In some embodiments, the subject is identified as suffering from nephrotoxicity. In some embodiments, the subject is identified as suffering from cardiac toxicity. In some embodiments, the subject is identified as having atherosclerosis. In some embodiments, the subject is a mechanically ventilated subject.

[0063] A method for treating an infectious disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an infectious disease via oral inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for pulmonary exposure and / or pulmonary vascular absorption and delivery to affected tissue outside the lung, wherein the disease is selected from viral infections. In some embodiments, the subject is confirmed to have smallpox. In some embodiments, the subject is confirmed to have cytomegalovirus (CMV). In some embodiments, the subject is confirmed to have varicella-zoster virus (VZV). In some embodiments, the subject is confirmed to have human immunodeficiency virus (HIV). In some embodiments, the subject is identified as having herpes simplex virus (HSV). In some embodiments, the subject is identified as having influenza virus. In some embodiments, the subject is identified as having polyomavirus BK (BKV). In some embodiments, the subject is identified as having measles virus. In some embodiments, the subject is identified as having mumps virus. In some embodiments, the subject is identified as having rubella virus. In some embodiments, the subject is identified as having poliovirus. In some embodiments, the subject is identified as having West Nile virus. In some embodiments, the subject is identified as having Lyme disease. In some embodiments, the subject is identified as having subacute atrophic encephalitis. In some embodiments, the subject is identified as having progressive multifocal leukoencephalopathy. In some embodiments, the subject is identified as having meningitis. In some embodiments, the subject is identified as having encephalitis. In some embodiments, the subject is identified as suffering from acute flaccid paralysis. In some embodiments, the subject is identified as suffering from poliovirus.In some embodiments, the subject is identified as having poliovirus disease. In some embodiments, the subject is identified as having herpes simplex encephalitis. In some embodiments, the subject is identified as having enterovirus disease. In some embodiments, the subject is identified as having Lyme meningitis. In some embodiments, the subject is identified as having eastern equine encephalitis. In some embodiments, the subject is identified as having western equine encephalitis. In some embodiments, the subject is identified as having St. Louis encephalitis. In some embodiments, the subject is identified as having hydrophobia. In some embodiments, the subject is identified as having La Crosse encephalitis. In some embodiments, the subject is identified as having progressive rubella panencephalitis. In some embodiments, the subject is identified as having varicella-zoster encephalitis. In some embodiments, the subject is identified as having acute measles encephalitis. In some embodiments, the subject is identified as having mumps meningoencephalitis. In some embodiments, the subject is a mechanically ventilated subject.

[0064] A method for treating an infectious disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, or a tyrosine kinase inhibitor or a salt thereof to the oral or nasal cavity of a subject suffering from or suspected of suffering from a neurological infection via oral or nasal inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is selected from viral infections. In some embodiments, the subject is confirmed to have cytomegalovirus (CMV). In some embodiments, the subject is confirmed to have varicella-zoster virus (VZV). In some embodiments, the subject is confirmed to have human immunodeficiency virus (HIV). In some embodiments, the subject is confirmed to have herpes simplex virus (HSV). In some embodiments, the subject is identified as having influenza virus. In some embodiments, the subject is identified as having polyomavirus BK (BKV). In some embodiments, the subject is identified as having measles virus. In some embodiments, the subject is identified as having mumps virus. In some embodiments, the subject is identified as having rubella virus. In some embodiments, the subject is identified as having poliovirus. In some embodiments, the subject is identified as having West Nile virus. In some embodiments, the subject is identified as having Lyme disease. In some embodiments, the subject is identified as having subacute atrophic encephalitis. In some embodiments, the subject is identified as having progressive multifocal leukoencephalopathy. In some embodiments, the subject is identified as having meningitis. In some embodiments, the subject is identified as having encephalitis. In some embodiments, the subject is identified as having acute flaccid paralysis. In some embodiments, the subject is identified as having poliovirus, hi some embodiments, the subject is identified as having poliovirus.In some embodiments, the subject is identified as having herpes simplex encephalitis. In some embodiments, the subject is identified as having an enteroviral disease. In some embodiments, the subject is identified as having Lyme meningitis. In some embodiments, the subject is identified as having eastern equine encephalitis. In some embodiments, the subject is identified as having western equine encephalitis. In some embodiments, the subject is identified as having St. Louis encephalitis. In some embodiments, the subject is identified as having hydrophobia. In some embodiments, the subject is identified as having La Crosse encephalitis. In some embodiments, the subject is identified as having progressive rubella panencephalitis. In some embodiments, the subject is identified as having varicella zoster encephalitis. In some embodiments, the subject is identified as having acute measles encephalitis. In some embodiments, the subject is identified as having mumps meningoencephalitis. In some embodiments, the subject is a subject on a mechanical ventilator. In one aspect, the present specification describes a method for treating a neurological disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the oral cavity or nasal cavity of a subject suffering from or suspected of having a neurological disease via oral or nasal inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is multiple sclerosis. In some embodiments, the subject is confirmed to have multiple sclerosis. In some embodiments, the subject is a subject on a mechanical ventilator.

[0065] In one aspect, the present specification describes a method for treating a neurological disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the oral or nasal cavity of a subject suffering from or suspected of having a neurological disease via oral or nasal inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is neurofibromatosis. In some embodiments, the subject is confirmed to have type 1 neurofibromatosis. In some embodiments, the subject is confirmed to have Alzheimer's disease. In some embodiments, the subject is confirmed to have opioid tolerance. In some embodiments, the subject is confirmed to have desmoidoma. In some embodiments, the subject is a mechanically ventilated subject.

[0066] In one aspect, the present specification describes a pharmaceutical composition for pulmonary delivery, the pharmaceutical composition comprising a dry powder containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, with a dosage content of greater than about 1%. In some embodiments, the dosage content is at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dosage content is at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dosage content is at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the content may be administered in one or more doses. In some embodiments, the powder may be delivered neat. In some embodiments, the powder further comprises a carrier agent.In some embodiments, the carrier agent is selected from the group consisting of lactose.

[0067] Effective drug delivery to the lungs via dry powder inhalers (DPIs) depends on various factors, including the inhaler device, formulation, and inhalation procedure. Preparing an ideal DPI formulation requires control of overall formulation characteristics at the fine particle and bulk levels to ensure drug delivery to the lower respiratory tract. In DPI formulations, it is common practice to mix micronized drug particles (less than 5 microns in size) with larger carrier particles to address flowability and dose variability issues. The typical drug concentration in drug-carrier DPI formulations is low (e.g., 1 part drug:67.5 parts carrier), but this can vary depending on the aerosol dispersion characteristics of the formulation. Therefore, during drug-carrier mixing, drug particles are expected to preferably adhere to the active binding sites (more adhesive regions) on the carrier surface and detach from the carrier surface after inhalation. Drug redispersion is considered crucial for drug particles to enter the deep lung airways. Typically, only a small amount of drug reaches the lower respiratory tract due to strong drug-carrier adhesion. In fact, drug redispersion depends on the balance between cohesion (between drug particles) and adhesive forces (between drug and carrier particles). To aerosolize drug particles, the patient's inhalation force must overcome the drug-carrier adhesive forces, which depend on the physicochemical properties of both the drug and carrier particles. Consequently, the characteristics of carrier particles must be well controlled in terms of size, morphology, plasma form, surface energy, etc. It has been reported that differences in carrier particle size can significantly affect DPI aerosolization performance. The presence of fine particles on the carrier surface can reduce the drug-carrier contact area and consequently the drug-carrier adhesive forces, leading to improved DPI performance. Better aerosolization performance was observed when the carrier tap density was higher, while no correlation was found between carrier flowability and DPI performance. Carriers with reduced dispersing surface energy produced larger drug fine particle fractions (FPFs) after aerosolization. Carrier particles with a larger elongation ratio or increased surface roughness exhibited favorable inhalation properties.

[0068] In one aspect, the present specification describes a pharmaceutical composition for pulmonary delivery, the pharmaceutical composition comprising a dry powder containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, with a dosage content of greater than about 1%. In another aspect, the present specification describes a disposable container, the container comprising about 0.01 mg to about 100 mg of dry powder containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, with a dosage content of greater than about 1%. In yet another aspect, the present specification describes a disposable container, the container comprising about 0.001 mg to about 200 mg of dry powder containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, with a dosage content of greater than about 1%. In a further aspect, the present specification describes a method for treating a pulmonary disease, comprising inhaling a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the dosage content is greater than about 1%. In some embodiments, the dosage content is at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dosage content is at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dosage content is at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and in some embodiments, the dose contains at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dry powder further comprises a carrier agent. In some embodiments, the carrier agent is lactose.

[0069] In one aspect, the present specification describes a method for treating a pulmonary disease, comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having interstitial lung disease via oral inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, having a dosage content of greater than about 1%. In another aspect, the present specification describes a disposable container containing about 0.01 mg to about 100 mg of dry powder containing imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, having a dosage content of greater than about 1%. In another aspect, the present specification describes a disposable container containing about 0.001 mg to about 200 mg of dry powder containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, with a dosage content of greater than about 1%. In some embodiments, the pulmonary disease is interstitial lung disease. In some embodiments, the interstitial lung disease is idiopathic pulmonary fibrosis. In some embodiments, the interstitial lung disease is radiation therapy-induced pulmonary fibrosis. In some embodiments, the pulmonary disease is chronic bronchitis. In some embodiments, the dry powder aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns. In some embodiments, the aerosol has a mean particle size of about 1 micron to about 5 microns in volumetric mean diameter and a geometric standard deviation of 3 microns or less. In some embodiments, the dose contains at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, hi some embodiments, the dose contains at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose content is at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step occurs within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within one breath.

[0070] In one aspect, provided herein is a method for administering an anti-fibrotic agent to the lungs of a subject, the method comprising introducing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof into a dry powder inhaler, the method having a dose content of greater than about 1%. In another aspect, provided herein is a method for treating an extrapulmonary disease target, the method comprising inhaling a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, the dose content being greater than about 1%. In some embodiments, the extrapulmonary disease target is the heart. In some embodiments, the extrapulmonary disease target is the kidney. In some embodiments, the extrapulmonary disease target is the liver. In some embodiments, the extrapulmonary disease target is a white blood cell. In some embodiments, the extrapulmonary disease target is a bone marrow. In another aspect, the present specification provides a method for treating a neurological disease, comprising oral or nasal inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the dose content is greater than about 1%. In some embodiments, the neurological disease is multiple sclerosis. In another aspect, the present specification provides a method for administering an anti-demylination agent to the nasal cavity of a subject, comprising introducing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, into a dry powder inhaler, wherein the dose content is greater than about 1%. In some embodiments, the dose content is at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, and in some embodiments, the dose contains at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dry powder contains a carrier agent. In some embodiments, the carrier agent is lactose. In some embodiments, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 5 microns. In some embodiments, the aerosol has a mean particle size volumetric mean diameter of about 1 micron to about 5 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the aerosol comprises particles having a mean aerodynamic diameter of about 1 micron to about 20 microns. In some embodiments, the aerosol has a mean particle size volumetric mean diameter of about 1 micron to about 20 microns and a geometric standard deviation of 3 microns or less. In some embodiments, the inhaling step delivers a dose of at least 0.001 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers In some embodiments, the inhalation step delivers a dose of at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 90 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 100 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 110 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 120 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 130 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation process delivers a dose of at least 140 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the inhalation step delivers a dose of at least 150 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 160 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 170 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhalation step delivers a dose of at least 180 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 190 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step delivers a dose of at least 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the inhaling step occurs within less than about 5 breaths. In some embodiments, the inhaling step occurs within less than about 3 breaths. In some embodiments, the inhaling step occurs within less than about 2 breaths. In some embodiments, the inhaling step occurs within a single breath. In some embodiments, the method further comprises opening a disposable dry powder container holding between about 0.01 mg and about 100 mg of imatinib or a salt thereof, or a phenylaminopyrimidine derivative or a salt thereof, for introduction into the dry powder inhaler. In some embodiments, the method further includes opening a disposable dry powder container holding between about 0.001 mg and about 200 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for introduction into the dry powder inhaler.

[0071] In one aspect, the present specification describes a method for treating a lung disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an interstitial lung disease via oral inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the disease is selected from interstitial lung diseases, including pulmonary hypertension. In some embodiments, the subject is confirmed to have an interstitial lung disease. In some embodiments, the subject is confirmed to have pulmonary hypertension. In some embodiments, the subject is confirmed to have portopulmonary hypertension. In some embodiments, the subject is a subject on a ventilator.

[0072] In one aspect, the present specification describes a method for treating a pulmonary disease, comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having a pulmonary disease via oral inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the pulmonary disease is cancer. In some embodiments, the lung cancer is small cell lung cancer. In some embodiments, the lung cancer is large cell carcinoma. In some embodiments, the lung cancer is mesothelioma. In some embodiments, the lung cancer is pulmonary carcinoid tumor or bronchial carcinoid. In some embodiments, the lung cancer is secondary lung cancer resulting from metastatic disease. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the lung cancer is bronchioloalveolar carcinoma. In some embodiments, the lung cancer may be a sarcoma. In some embodiments, the lung cancer can be lymphoma. In some embodiments, the subject is a mechanically ventilated subject.

[0073] A method for treating an extrapulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an extrapulmonary cancer via oral inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, wherein the disease is selected from localized cancers including leukemia and lymphoma. In some embodiments, the subject is confirmed to have chronic myeloid leukemia (CML). In some embodiments, the subject is confirmed to have gastrointestinal stromal tumor (GIST). In some embodiments, the subject is confirmed to have relapsed or refractory Ph-positive acute lymphoblastic leukemia (ALL). In some embodiments, the subject is identified as having a myelodysplastic / myeloproliferative disorder associated with a platelet-derived growth factor receptor gene rearrangement. In some embodiments, the subject is identified as having aggressive systemic mastocytosis (ASM) with or without an unknown D816V c-KIT mutation. In some embodiments, the subject is a mechanically ventilated subject. In some embodiments, the subject is identified as having hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukemia (CEL), and the subject has FIP1L1-PDGFRα fusion kinase (CHIC2 allele deletion) or a negative or unknown FIP1L1-PDGFR-alpha fusion kinase. In some embodiments, the subject is identified as having unresectable, recurrent, and / or metastatic dermatofibrosarcoma protuberans.

[0074] A method for treating an extrapulmonary disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof via oral inhalation of a dry powder aerosol comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having a disease associated with extrapulmonary fibrosis, inflammation, and / or toxicity, for pulmonary vascular absorption and delivery to the affected tissue outside the lung, wherein the disease is selected from cardiac fibrosis, renal fibrosis, hepatic fibrosis, nephrotoxicity, and cardiac toxicity. In some embodiments, the subject is identified as suffering from cardiac fibrosis. In some embodiments, the subject is identified as suffering from renal fibrosis. In some embodiments, the subject is identified as suffering from hepatic fibrosis. In some embodiments, the subject is identified as suffering from nephrotoxicity. In some embodiments, the subject is identified as suffering from cardiac toxicity. In some embodiments, the subject is identified as having atherosclerosis. In some embodiments, the subject is a mechanically ventilated subject.

[0075] A method for treating an infectious disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the middle to lower respiratory tract of a subject suffering from or suspected of having an infectious disease via oral inhalation of a dry powder aerosol comprising imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for pulmonary exposure and / or pulmonary vascular absorption and delivery to affected tissue outside the lung, wherein the disease is selected from viral infections. In some embodiments, the subject is confirmed to have smallpox. In some embodiments, the subject is confirmed to have cytomegalovirus (CMV). In some embodiments, the subject is confirmed to have varicella-zoster virus (VZV). In some embodiments, the subject is confirmed to have human immunodeficiency virus (HIV). In some embodiments, the subject is identified as having herpes simplex virus (HSV). In some embodiments, the subject is identified as having influenza virus. In some embodiments, the subject is identified as having polyomavirus BK (BKV). In some embodiments, the subject is identified as having measles virus. In some embodiments, the subject is identified as having mumps virus. In some embodiments, the subject is identified as having rubella virus. In some embodiments, the subject is identified as having poliovirus. In some embodiments, the subject is identified as having West Nile virus. In some embodiments, the subject is identified as having Lyme disease. In some embodiments, the subject is identified as having subacute atrophic encephalitis. In some embodiments, the subject is identified as having progressive multifocal leukoencephalopathy. In some embodiments, the subject is identified as having meningitis. In some embodiments, the subject is identified as having encephalitis. In some embodiments, the subject is identified as suffering from acute flaccid paralysis. In some embodiments, the subject is identified as suffering from poliovirus.In some embodiments, the subject is identified as having poliovirus disease. In some embodiments, the subject is identified as having herpes simplex encephalitis. In some embodiments, the subject is identified as having enterovirus disease. In some embodiments, the subject is identified as having Lyme meningitis. In some embodiments, the subject is identified as having eastern equine encephalitis. In some embodiments, the subject is identified as having western equine encephalitis. In some embodiments, the subject is identified as having St. Louis encephalitis. In some embodiments, the subject is identified as having hydrophobia. In some embodiments, the subject is identified as having La Crosse encephalitis. In some embodiments, the subject is identified as having progressive rubella panencephalitis. In some embodiments, the subject is identified as having varicella-zoster encephalitis. In some embodiments, the subject is identified as having acute measles encephalitis. In some embodiments, the subject is confirmed to have mumps meningoencephalitis. In some embodiments, the subject is a mechanically ventilated subject.

[0076] A method for treating an infectious disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the oral or nasal cavity of a subject suffering from or suspected of suffering from a neurological infection via oral or nasal inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is selected from viral infections. In some embodiments, the subject is confirmed to have cytomegalovirus (CMV). In some embodiments, the subject is confirmed to have varicella-zoster virus (VZV). In some embodiments, the subject is confirmed to have human immunodeficiency virus (HIV). In some embodiments, the subject is confirmed to have herpes simplex virus (HSV). In some embodiments, the subject is confirmed to have influenza virus. In some embodiments, the subject is identified as having polyomavirus BK (BKV). In some embodiments, the subject is identified as having measles virus. In some embodiments, the subject is identified as having mumps virus. In some embodiments, the subject is identified as having rubella virus. In some embodiments, the subject is identified as having poliovirus. In some embodiments, the subject is identified as having West Nile virus. In some embodiments, the subject is identified as having Lyme disease. In some embodiments, the subject is identified as having subacute atrophic encephalitis. In some embodiments, the subject is identified as having progressive multifocal leukoencephalopathy. In some embodiments, the subject is identified as having meningitis. In some embodiments, the subject is identified as having encephalitis. In some embodiments, the subject is identified as having acute flaccid paralysis. In some embodiments, the subject is identified as having poliovirus. In some embodiments, the subject is identified as having polio.In some embodiments, the subject is identified as having herpes simplex encephalitis. In some embodiments, the subject is identified as having an enteroviral disease. In some embodiments, the subject is identified as having Lyme meningitis. In some embodiments, the subject is identified as having eastern equine encephalitis. In some embodiments, the subject is identified as having western equine encephalitis. In some embodiments, the subject is identified as having St. Louis encephalitis. In some embodiments, the subject is identified as having hydrophobia. In some embodiments, the subject is identified as having La Crosse encephalitis. In some embodiments, the subject is identified as having progressive rubella panencephalitis. In some embodiments, the subject is identified as having varicella zoster encephalitis. In some embodiments, the subject is identified as having acute measles encephalitis. In some embodiments, the subject is identified as having mumps meningoencephalitis. In some embodiments, the subject is a subject on a mechanical ventilator. In one aspect, the present specification describes a method for treating a neurological disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the oral cavity or nasal cavity of a subject suffering from or suspected of having a neurological disease via oral or nasal inhalation of an aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is multiple sclerosis. In some embodiments, the subject is confirmed to have multiple sclerosis. In some embodiments, the subject is a subject on a mechanical ventilator.

[0077] In one aspect, the present specification describes a method for treating a neurological disease, the method comprising administering imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof to the oral or nasal cavity of a subject suffering from or suspected of having a neurological disease via oral or nasal inhalation of a dry powder aerosol containing imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof, for pulmonary or nasal vascular absorption and delivery to the central nervous system, wherein the disease is neurofibromatosis. In some embodiments, the subject is confirmed to have type 1 neurofibromatosis. In some embodiments, the subject is confirmed to have Alzheimer's disease. In some embodiments, the subject is confirmed to have opioid tolerance. In some embodiments, the subject is confirmed to have desmoidoma. In some embodiments, the subject is a mechanically ventilated subject.

[0078] In one aspect, the present specification describes a kit comprising: a pharmaceutical composition comprising a dry powder formulation of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in a container, wherein the dosage content of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than 1%; and a dry powder inhaler adapted to aerosolize the dry powder formulation of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for delivery to the middle to lower respiratory tract via oral inhalation. In another aspect, the present specification describes a kit comprising: a pharmaceutical composition containing a formulation of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof in a container, wherein the dosage content of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof is greater than 1%; and a dry powder inhaler adapted to aerosolize the dry powder formulation of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof for delivery to the nasal cavity via nasal inhalation. In some embodiments, the dosage content is at least 0.005 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.01 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.05 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 0.1 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 0.5 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 1.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 2.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 4.0 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 8 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 12 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 16 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 20 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 30 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 40 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 50 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof.In some embodiments, the dose contains at least 60 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 70 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase inhibitor or a salt thereof. In some embodiments, the dose contains at least 80 mg of imatinib or a salt thereof, a phenylaminopyrimidine derivative or a salt thereof, or another tyrosine kinase i...

Claims

1. 1. A pharmaceutical composition for nebulized inhalation administration to achieve a reduction in the decline in forced vital capacity (FVC) in pulmonary disease in adults, the pharmaceutical composition comprising from about 0.01 mL to about 10 mL of an aqueous solution having a concentration of from about 0.01 mg / mL to about 100 mg / mL of a nintedanib salt, the aqueous solution having an osmolality of from about 50 mOsmol / kg to about 2000 mOsmol / kg and a concentration of permeant ions of from about 30 mM to about 300 mM, and contained in a reservoir of a liquid nebulizer for inhalation delivery of the aqueous solution at a rate of between about 0.1 mL / min and about 1.0 mL / min.

2. 10. The pharmaceutical composition of claim 1, wherein the aqueous solution further comprises a buffer that is a citrate buffer, a fumarate buffer, or a phosphate buffer, or a combination thereof.

3. 2. The pharmaceutical composition of claim 1, wherein the pH of the aqueous solution is from about pH 4.0 to about pH 8.

0.

4. The pharmaceutical composition of claim 1 , wherein the aqueous solution further comprises an inorganic salt.

5. 10. The pharmaceutical composition of claim 1 for use in a method for treating a fibrotic lung disease or a lung cancer disease in an adult comprising administering the aqueous solution by inhalation to an adult, thereby reducing the decline in forced vital capacity in the adult.

6. 6. The pharmaceutical composition of claim 5, wherein the aqueous solution is administered by the liquid nebulizer to achieve a pulmonary deposition of at least 7% of the nintedanib salt in the lungs.

7. 2. The pharmaceutical composition of claim 1, wherein the liquid nebulizer is a liquid nebulizer that produces an aerosol of nintedanib salt having a geometric standard deviation (GSD) of the emitted droplet size distribution of the aqueous solution of about 1.0 μm to about 2.5 μm and a median aerodynamic diameter (MMAD) of the droplet size of the aqueous solution emitted by the liquid nebulizer of about 1 μm to about 5 μm.

8. 8. The pharmaceutical composition of claim 7, wherein the liquid nebulizer provides an output rate of at least 0.1 mL / min and / or delivers at least about 25% of the aqueous solution to an adult human by inhalation.

9. 8. The pharmaceutical composition of claim 7, comprising delivering said aqueous solution to the lungs of an adult human in a particle size of about 1 to about 5 microns mass median aerodynamic diameter (MMAD) in less than 20 minutes.

10. 5. The pharmaceutical composition of claim 4, wherein the inorganic salts have a concentration of from about 0.1% to about 1.0%.

11. 2. The pharmaceutical composition of claim 1, wherein the permeant ion is chloride or bromide.

12. 10. The pharmaceutical composition of claim 1, further comprising at least one ingredient selected from the group consisting of magnesium chloride, ethanol, polypropylene glycol, glycerin, polysorbate 80, cetylpyridinium bromide, cetylpyridinium chloride, fructose, glucose, lactose, sucrose, mannitol, and sodium chloride, and combinations thereof.

13. 5. The pharmaceutical composition of claim 4, wherein the inorganic salts are selected from the group consisting of sodium chloride, magnesium chloride, sodium bromide, calcium chloride, and calcium bromide, and wherein the total amount of the inorganic salts is from about 0.01 to 2.0% w / w of the aqueous solution.

Citation Information

Patent Citations

  • Methods, devices and formulations for targeted endobronchial therapy

    JP2006512184A

  • Drugs for the treatment or prevention of fibrosis

    JP2008525370A

  • Aerosol pirfenidone and pyridone analog compounds and uses thereof

    WO2012106382A1

  • Pharmaceutical composition for inhalation

    WO2013039167A1

  • Aerosolized fluoroquinolones and their uses

    JP2008540676A